NCT03554876

Brief Summary

This study evaluates the efficacy of Mutli-Im® transepithelial components in the inhibition of bacterial adhesion. The control group will be the Multi-Im® transepithelial component with the conventional surface (Multi-IM® Machined) and the experimental group will be the Multi-Im transepithelial components with the Ti-Golden® surface (Multi-Im Golden) or with the nanogolden surface (Multi-Im® nanogolden). Periodontal indices and biofilformation will be assessed during 2 months after implant loading. Metagenomic analysis and PCR technique will be implemented to assess the biofilm formation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 30, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 13, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

July 16, 2018

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2020

Completed
Last Updated

February 25, 2025

Status Verified

February 1, 2025

Enrollment Period

2.4 years

First QC Date

May 30, 2018

Last Update Submit

February 24, 2025

Conditions

Keywords

Biofilmperi-implantitismetagenomic analysisabutment

Outcome Measures

Primary Outcomes (2)

  • Total amount of the 25 most relevant bacterial species in peri-implantitis processes measured in the retired Multi-Im implants

    24 hours

  • Total amount of the 25 most relevant bacterial species in peri-implantitis processes

    2 months

Secondary Outcomes (5)

  • Total number of bacterial species.

    24 hours, 2 months

  • Total amount of the 6 most abundant bacterial species.

    24 hours, 2 months

  • Dental plaque index

    Baseline, 24 hours, 2 months

  • Gingival index of the natural teeth

    Baseline, 24 hours, 2 months

  • Probing depth of natural teeth

    Baseline, 24 hours, 2 months

Study Arms (3)

Multi-Im Machined

ACTIVE COMPARATOR

Multi-Im Machined

Device: Multi-Im Machined transepithelial component.

Multi-Im® nanogolden

EXPERIMENTAL

Multi-Im® nanogolden

Device: Multi-Im Nanogolden transepithelial component

Multi-Im T-Golden

EXPERIMENTAL

Multi-Im T-Golden

Device: Multi-Im Ti-Golden transepithelial component

Interventions

Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.

Multi-Im Machined

Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.

Multi-Im® nanogolden

Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.

Multi-Im T-Golden

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indication of having to place at least three dental implants.
  • Plate index ≤ 20% and absence of evidence of active periodontal disease.
  • Bleeding index of adjacent teeth ≤ 30%.
  • Probing depth in adjacent teeth \<4 mm.
  • Not having used systemic antibiotics during the last 6 months.
  • Non smoker.
  • Possibility for observation during the treatment period.
  • Having signed the informed consent.

You may not qualify if:

  • Suffering any alteration or serious hematologic disease.
  • radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids and/or anticoagulants.
  • Presence of malignant tumors, hemangiomas or angiomas in the area of implant placement.
  • Patients undergoing treatment with bisphosphonate drugs, both orally and intravenously.
  • Metabolic bone disease.
  • Diseases that affect the oral mucosa.
  • Diabetic patients.
  • Severe parafunctional habits and/or temporomandibular joint disorders.
  • Pregnant or lactating women.
  • Physical or mental inability to maintain a good oral hygiene.
  • Being participating in another study.
  • In general, any inability to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clínica Eduardo Anitua

Vitoria-Gasteiz, Spain

Location

Related Publications (1)

  • Anitua E, Murias-Freijo A, Tierno R, Tejero R, Alkhraisat MH. Assessing peri-implant bacterial community structure: the effect of microbiome sample collection method. BMC Oral Health. 2024 Aug 26;24(1):1001. doi: 10.1186/s12903-024-04675-y.

MeSH Terms

Conditions

Peri-Implantitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2018

First Posted

June 13, 2018

Study Start

July 16, 2018

Primary Completion

December 22, 2020

Study Completion

December 22, 2020

Last Updated

February 25, 2025

Record last verified: 2025-02

Locations